TAG-72 Antibody (0.N.562): sc-59711

TAG-72 Antibody (0.N.562) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) in mouse, rat, human, and bovine samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein predominantly localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for various cancers. TAG-72 expression is notably high in 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues, which underscores TAG-72′s potential as a diagnostic and therapeutic target. Additionally, TAG-72 is significantly expressed in low-grade mucoepidermoid carcinomas and is associated with several gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas. TAG-72 expression levels also provide insights into tumor differentiation, as seen in human prostatic adenocarcinomas where TAG-72 expression negatively correlates with the Gleason grade. Furthermore, TAG-72 is instrumental in the purification of primary ovarian cancer cells from patient ascites, highlighting TAG-72′s utility in both research and clinical settings. With broad reactivity and application versatility, anti-TAG-72 antibody (0.N.562) is an essential tool for researchers investigating cancer biology and potential therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (0.N.562) References:

1. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.  |  Kelly, FJ., et al. 2000. Clin Cancer Res. 6: 4323-33. PMID: 11106250
2. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.  |  Chauhan, SC., et al. 2007. J Histochem Cytochem. 55: 867-75. PMID: 17478446
3. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.  |  Zou, P., et al. 2010. World J Surg Oncol. 8: 65. PMID: 20691066
4. Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.  |  Chen, L., et al. 2011. Nucl Med Commun. 32: 920-4. PMID: 21876403
5. Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers.  |  Motoo, Y., et al. 1990. Oncology. 47: 456-62. PMID: 2243663
6. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer.  |  Xu, M., et al. 1989. Int J Cancer. 44: 985-9. PMID: 2481651
7. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.  |  Hege, KM., et al. 2017. J Immunother Cancer. 5: 22. PMID: 28344808
8. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.  |  Brenner, PC., et al. 1995. J Urol. 153: 1575-9. PMID: 7536270
9. Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma.  |  González, A., et al. 1996. Int J Biol Markers. 11: 165-71. PMID: 8915712
10. TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.  |  Nicolet, CM., et al. 1997. Tumour Biol. 18: 356-66. PMID: 9372869

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.